TargetBeta
CD40
CD40 molecule · also p50, Bp50, TNFRSF5 · CD molecules
2 programs in company-led studies act on CD40, from 2 companies: 0 in phase 3. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (1 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| TQB2916 | Sino Biopharmaceutical | phase 2 | 32 running | – | the company's pipeline |
| Anti-MUC-1/Anti-CD40 Bispecific Antibody M0324rule | Merck KGaA, Darmstadt, Germany | phase 1 | 11 running | MUC1 | NCIt |
Also acted on by the same programs
Conditions their studies are in
- Carcinoma, Non-Small-Cell Lung, 1 program
- Pancreatic Neoplasms, 1 program
- Sarcoma, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Aug 2027TQB2916 · Sino Biopharmaceutical · phase 2 · NCT06962267
- Feb 23, 2029Anti-MUC-1/Anti-CD40 Bispecific Antibody M0324 · Merck KGaA, Darmstadt, Germany · phase 1 · NCT07166601
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.